Valuation: Standard BioTools Inc.

Market Cap 313M 272M 255M 233M 440M 29.84B 445M 2.98B 1.17B 14.91B 1.18B 1.15B 49.62B P/E 2026 *
-8x
P/E 2027 * -5x
Enterprise Value 313M 272M 255M 233M 440M 29.84B 445M 2.98B 1.17B 14.91B 1.18B 1.15B 49.62B EV / Sales 2026 *
3.8x
EV / Sales 2027 * 3.72x
Free-Float
93.41%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Standard BioTools Inc.

1 day+2.04%
1 week-10.83%
Current month-7.82%
1 month-9.83%
3 months-17.39%
6 months-36.50%
Current year-37.49%
1 week 0.77
Extreme 0.7674
0.91
1 month 0.77
Extreme 0.76595
0.97
Current year 0.7
Extreme 0.7029
1.67
1 year 0.7
Extreme 0.7029
1.72
3 years 0.7
Extreme 0.7029
3.16
5 years 0.7
Extreme 0.7029
7.31
10 years 0.7
Extreme 0.7029
14.9
Manager TitleAgeSince
Director of Finance/CFO 55 2024-08-31
Chief Executive Officer 63 2021-09-30
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 72 2022-03-31
Director/Board Member 53 2022-04-03
Director/Board Member 63 2021-09-30
Date Insider Type Main position Quantity % Market Cap.
8/3/26 Tax

Chief Executive Officer

-362,625 0.0929%
7/23/26 Tax

Founder

-202,476 0.0519%
6/18/26 Free

Director

275,039 0.0705%
Change 5-day change 1-year change 3-year change Capi.($)
+2.04%-10.83%-37.49%-68.50% 313M
+0.38%+0.56%+29.20%+5.72% 214B
+0.16%+1.94%+2.46%-21.50% 141B
-0.40%+5.88%-21.17%+20.82% 132B
+3.27%+7.17%-52.11%-2.80% 71.45B
+0.39%+2.76%+13.62%+12.28% 51.48B
-0.36%+5.11%-14.27%-20.67% 50.15B
+0.16%+1.90%+24.83%+11.91% 39.92B
-0.08%+5.10%+43.92%+37.88% 39.24B
-0.35%+7.04%-20.40%+24.54% 32.2B
Average +0.52%+2.82%-3.14%-0.03% 77.18B
Weighted average by Cap. +0.36%+3.41%+2.75%+3.99%

Financials

2026 *2027 *
Net sales 82.5M 71.59M 67.04M 61.32M 116M 7.86B 117M 784M 308M 3.93B 310M 303M 13.07B 84.1M 72.98M 68.34M 62.51M 118M 8.01B 120M 799M 314M 4B 316M 309M 13.32B
Net income -38.8M -33.67M -31.53M -28.84M -54.45M -3.7B -55.16M -369M -145M -1.85B -146M -143M -6.15B -62.9M -54.58M -51.11M -46.75M -88.27M -5.99B -89.42M -598M -235M -2.99B -236M -231M -9.96B
Net Debt - -
Logo Standard BioTools Inc.
Standard BioTools Inc. has a portfolio of technologies that help biomedical researchers develop medicines faster. The Company develops, manufactures and sells a diversified range of instrumentation, consumables, and services. The Company's Genomics business includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. Its Biomark X9 system for high-throughput genomics delivers scalability for qPCR applications. Designed for researchers who require robust multiplexing capabilities, the Biomark X9 system enables the simultaneous analysis of thousands of reactions in a single run. By leveraging advanced microfluidics technology, it reduces reagent consumption while increasing throughput, making it a solution for large-scale genomic studies, clinical research, and biomarker discovery. The Biomark X9 system integrates with data analysis tools, accelerating workflows and providing comprehensive insights.
Employees
387
Date Price Change Volume
26-08-06 US$0.8001 +2.04% 1,107,358
26-08-05 US$0.7841 -4.44% 2,154,418
26-08-04 US$0.8205 -5.28% 1,196,710
26-08-03 US$0.8662 -0.21% 1,290,149
26-07-31 US$0.8680 -3.27% 1,258,263
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.8001USD
Average target price
1.550USD
Spread / Average Target
+93.73%

Quarterly revenue - Rate of surprise